Last reviewed · How we verify
Iodinated Contrast Media (ICM)
Iodinated contrast media absorb X-rays to enhance visualization of blood vessels, organs, and tissues during radiographic imaging procedures.
Iodinated contrast media absorb X-rays to enhance visualization of blood vessels, organs, and tissues during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and renal imaging.
At a glance
| Generic name | Iodinated Contrast Media (ICM) |
|---|---|
| Sponsor | University of Leipzig |
| Drug class | Radiographic contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
ICM contains iodine atoms that have high atomic number and density, making them radiopaque and able to attenuate X-rays more effectively than surrounding soft tissue. When injected intravenously or administered orally, ICM distributes through the vasculature and target organs, creating enhanced contrast in radiographic images. This allows clinicians to visualize vascular anatomy, perfusion, and organ function during angiography, CT, and other imaging studies.
Approved indications
- Contrast enhancement for angiography and vascular imaging
- Contrast enhancement for computed tomography (CT) imaging
- Contrast enhancement for urography and renal imaging
Common side effects
- Contrast-induced nephropathy (acute kidney injury)
- Allergic reaction (mild to severe)
- Thyroid dysfunction (iodine-related)
- Nausea and vomiting
- Hypersensitivity reactions
Key clinical trials
- A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE) (PHASE3)
- Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms (NA)
- CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study (PHASE4)
- Screening Contrast-Enhanced Mammography as an Alternative to MRI (PHASE4)
- Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)
- Carbon Dioxide Versus Iodine Contrast for Endovascular Revascularization of Aortoiliac Occlusive Disease (NA)
- Assessment of Differential Renal Function by CT in Living Donors (NA)
- Iodinated Contrast Media Induced Hyperthyroidism
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodinated Contrast Media (ICM) CI brief — competitive landscape report
- Iodinated Contrast Media (ICM) updates RSS · CI watch RSS
- University of Leipzig portfolio CI